证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-023 受理号：CXHL2400083 药物类型：化学药品 注册分类：1类 江苏恒瑞医药股份有限公司 关于药物纳入突破性治疗品种名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日,江苏恒瑞医药股份有限公司（以下简称"公司"）的HRS-4642注射液被 国家药品监督管理局药品审评中心（以下简称"药审中心"）纳入突破性治疗品 种名单。现将相关情况公告如下： 一、药物的基本情况 药物名称：HRS-4642注射液 江苏恒瑞医药股份有限公司董事会 2026 年 2 月 6 日 申请日期：2025年12月24日 拟定适应症（或功能主治）：本品联合吉西他滨和紫杉醇（白蛋白结合型） 用于携带KRAS G12D突变的晚期或转移性胰腺癌的一线治疗。 理由及依据：经审核，本申请符合《药品注册管理办法》和《国家药监局关 于发布＜突破性治疗药物审评工作程序（试行）＞等三个文件的公告》（2020年 第82号）有关要求，同意纳入突破性治疗药物程序。 二、药物的其他相关情况 胰腺 ...

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting first-line treatment for advanced or metastatic pancreatic cancer with KRAS G12D mutation [1] Group 1: Drug Development - The proposed indication for HRS-4642 is in combination with gemcitabine and albumin-bound paclitaxel [1] - The total research and development investment for the related project has reached approximately 254 million yuan [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1]

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting first-line treatment for advanced or metastatic pancreatic cancer with KRAS G12D mutation [1] Group 1: Product Development - HRS-4642 is a liposomal formulation KRAS G12D inhibitor that specifically binds to KRAS G12D, inhibiting the phosphorylation of MEK and ERK proteins to exert anti-tumor effects [1] - The total R&D investment for the related project has reached approximately 254 million yuan [1] Group 2: Regulatory and Market Context - The inclusion in the breakthrough therapy list indicates potential expedited development and approval processes, which may enhance market opportunities for the product [1] - Drug development is subject to various uncertainties related to technology, approval, and policy factors [1]

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the Drug Review Center, aimed at treating advanced or metastatic pancreatic cancer with KRASG12D mutations [1] Group 1: Product Development - HRS-4642 is a Class 1 chemical drug developed by the company, intended for first-line treatment of pancreatic cancer with KRASG12D mutations [1] - The drug is expected to be submitted for approval by December 24, 2025 [1] - The total research and development investment for this project has reached approximately 254 million yuan [1] Group 2: Market Context - There are currently no similar drugs approved for market, both domestically and internationally, indicating a potential competitive advantage for the company [1] - The development of the drug is subject to various factors that may introduce uncertainty risks [1]

Group 1: JPM Conference Overview - The J.P. Morgan Healthcare Conference is one of the largest and most influential gatherings in the global healthcare sector, covering pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, and healthcare services [3] - The conference serves as a platform for multinational corporations (MNCs), biotech firms, and investment institutions to connect, providing clear signals for industry development over the coming year [4] - The 2026 JPM Conference will be held from January 12 to 15 in San Francisco, California [5] Group 2: MNC Strategic Positioning and BD Strategies - In 2026, MNCs are focusing on four key areas: neuroscience, immunology, oncology, and cardiovascular diseases [6] - Business development (BD) transactions are becoming a core strategy for MNCs, with a shift towards precision and rationality in BD deals, emphasizing next-generation immunotherapies, cell therapies, and gene therapies [6] - AI is increasingly integrated into drug development, clinical design, and operational management across the industry [6][18] Group 3: Investment Opportunities in Innovative Drugs - The acceleration of BD transactions abroad is expected to inject new performance growth and market value elasticity, with a notable increase in projects and upfront payments in 2025 [8] - Policy support for innovative drugs is improving, with recent measures from health authorities aimed at fostering high-quality development in the sector [8] - Key clinical data releases and commercialization milestones for several innovative drugs are anticipated in 2025, which could significantly impact market valuations [8] Group 4: Key Domestic Companies and Their Focus - Companies like Hengrui Medicine and BeiGene are expected to achieve significant milestones in 2026, including multiple new drug applications and clinical data releases [24][25] - Hengrui Medicine aims to leverage a dual strategy of R&D and BD, with over 25 ongoing Phase III clinical trials and a target of more than 10 new drug approvals [24] - BeiGene is positioned to capitalize on its leading products in the chronic lymphocytic leukemia (CLL) space, with several key regulatory submissions and clinical trials planned for 2026 [29][35]

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Add" for 药明康德 (WuXi AppTec) [6][53]. Core Insights - The report highlights the recent approval of new drugs, including 埃诺格鲁肽注射液 (Energulutide Injection), which is the first of its kind approved for adult type 2 diabetes patients [16]. - The report emphasizes the importance of the recent policies from the National Medical Security Administration aimed at enhancing the medical insurance landscape, which is expected to improve service levels and create development opportunities in the industry [14]. - The report notes significant growth in product revenues for companies like 信达生物 (Innovent Biologics) and 康方生物 (CanSino Biologics), indicating a positive trend in the sector [31][32]. Industry News - The National Medical Security Administration issued a notice to accelerate the cultivation and application of new scenarios in the medical insurance field, which is expected to enhance service levels and create industry development opportunities [14]. - The Ministry of Industry and Information Technology, along with seven other departments, released a plan for the high-quality development of the traditional Chinese medicine industry from 2026 to 2030, aiming to strengthen the entire industry chain [15]. - The report mentions that in 2025, the employee medical insurance personal account had a total of 4.64 billion person-times, with a total amount of 68.77 billion yuan [15]. Company Announcements - 信达生物 (Innovent Biologics) reported a strong revenue growth of approximately 45% year-on-year for 2025, with a significant increase in Q4 revenue due to new drugs being included in the national medical insurance directory [31]. - 康方生物 (CanSino Biologics) granted exclusive commercialization rights for 伊喜宁® (Evinacumab) to 济川药业 (Jichuan Pharmaceutical), receiving an upfront payment of 80 million yuan [32]. - 恒瑞医药 (Hengrui Medicine) has had several drug applications accepted by the FDA and NMPA, indicating ongoing progress in its product pipeline [33]. Market Review - The report notes a decline in major indices, with the SW Pharmaceutical and Biological sector down by 0.97% during the week of January 30 to February 5, 2026 [45]. - The overall industry P/E ratio as of February 5, 2026, was reported at 51.01 times, with a valuation premium of 261% relative to the CSI 300 index [47]. Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring companies involved in small nucleic acids and AI applications [53].

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-1894 injection, aimed at treating atopic dermatitis, marking a significant development as no similar drugs have been approved domestically or internationally [1] Company Summary - The company has invested 40.1 million yuan in the SHR-1894 project [1]

Group 1: Market Overview - The global sales of GLP-1 drugs have surpassed Merck's Keytruda, with Eli Lilly's Tirzepatide generating $36.5 billion and Novo Nordisk's Semaglutide achieving $36.1 billion in 2025 [1] - The sales of Tirzepatide's weight loss indication increased by 175% year-on-year, while the diabetes indication grew by 99% [1] - The potential patient market for weight loss is significantly large, indicating a strong demand for GLP-1 drugs [1] Group 2: Company Developments - Several domestic companies, including Innovent Biologics, Jiangsu Hengrui Medicine, Tonghua Dongbao, and East China Pharmaceutical, are actively developing GLP-1 drugs to meet weight loss market demands [2] - Innovent Biologics' GLP-1 weight loss drug, Sema, has been approved for sale in China, contributing to the company's revenue growth, which is expected to exceed 10 billion yuan in 2025 [3] - Hengrui Medicine is developing HRS9531, which shows promising results in weight loss and blood sugar control, while also improving cardiovascular and renal risk factors [4] Group 3: Competitive Strategies - Companies are adopting differentiated strategies in drug development, such as creating oral formulations, extending drug half-lives, and innovating sales models [5] - Hengrui Medicine is focusing on developing a GLP-1/GIP dual receptor agonist, which aims to enhance efficacy and safety [5] - Tonghua Dongbao is also working on a GLP-1/GIP dual receptor agonist, with clinical trials progressing smoothly [5] Group 4: Research and Development Focus - Innovent Biologics is expanding its research pipeline to include long-acting, oral, and multi-target projects, aiming to provide more effective treatment options [6] - East China Pharmaceutical is developing an oral small molecule GLP-1 drug, with successful completion of all subject enrollments for its clinical phase III study in weight management [6]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-1894 injection, a self-developed biological product aimed at treating atopic dermatitis [1] Group 1 - SHR-1894 injection is expected to protect the skin barrier and suppress inflammation during the treatment of atopic dermatitis [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1]

Core Viewpoint - Heng Rui Medicine has received acceptance for its HR091506 tablet application from the National Medical Products Administration, aimed at long-term treatment of hyperuricemia in gout patients [1] Group 1 - The HR091506 tablet is developed using gastric retention formulation technology and features a pulsatile release characteristic [1] - The product consists of a rapid-release part and a delayed-release part, designed to quickly achieve effective blood drug concentration and maintain it over an extended period [1] - The goal of HR091506 is to improve the rate of achieving target uric acid levels in patients [1]